 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wedbush reaffirmed their outperform rating on shares of Disc Medicine (NASDAQ:IRON - Free Report) in a report issued on Monday morning, RTT News reports. Wedbush currently has a $43.00 price...

Disc Medicine (NASDAQ:IRON) Given "Outperform" Rating at Wedbush

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Stock analysts at Leerink Partnrs reduced their Q2 2024 earnings per share estimates for shares of Disc Medicine in a report issued on Monday, April...

Leerink Partnrs Comments on Disc Medicine, Inc.'s Q2 2024 Earnings (NASDAQ:IRON)

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Wedbush boosted their FY2024 earnings per share (EPS) estimates for Disc Medicine in a report released on Monday, April 1st. Wedbush analyst D...

FY2024 Earnings Estimate for Disc Medicine, Inc. Issued By Wedbush (NASDAQ:IRON)

Disc Medicine (NASDAQ:IRON - Get Free Report)s stock had its "outperform" rating reaffirmed by analysts at Raymond James in a report issued on Monday, Marketbeat Ratings reports. They...

Raymond James Reiterates "Outperform" Rating for Disc Medicine (NASDAQ:IRON)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Assembly Biosciences (ASMB Research Report), Nater...

Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Natera (NTRA) and Disc Medicine (IRON)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Disc Medicine price target lowered by $30 at BMO Capital, here's why

Disc Medicine price target lowered by $33 at Stifel, here's why

This is a signal that IRON's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Disc Medicine (IRON, $34.31) RSI Indicator left the oversold zone on April 01, 2024

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report)'s stock price traded down 7.5% during trading on Tuesday after Stifel Nicolaus lowered their price target on the stock from $104.00 to $71.00...

Disc Medicine (NASDAQ:IRON)  Shares Down 7.5%  Following Analyst Downgrade

Disc Medicine's mid-stage study of bitopertin in patients with EPP met main goal...

Disc Medicine's mid-stage study of bitopertin in patients with EPP met main goal

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel treatments for hematologic disorders. Its programs include Bitopertin, DISC-0974, and DISC-3405. The company was founded in October 2017 and is headquartered in Watertown, MA.

Volume (M)	285,936.00
52-Wk High	$77.60
52-Wk Low	$23.30

IRON Disc Medicine Inc

About

Feed

News

Sentiment

Earnings

Fundamentals